Congratulations to HK Acquisition Corporation (07841.HK) on its Successful Listing on the Mainboard of HKSE on 15 August 2022. AVISTA Group is honored to be engaged in providing valuation services in relation to the fair value assessment of listed warrants and promoter warrants.
 
HK Acquisition Corporation is a special purpose acquisition company (SPAC) that intends to focus on companies in financial services and technology sectors that have competitive edges on sustainability and corporate governance and with operations or prospective operations in the Greater China area as its de-SPAC target.
<img src="../../../../../uploads/EN_b00e2348a8.png" alt="" width="960" height="720" />

 Congratulations to HK Acquisition Corporation (07841.HK) on its Successful Listing 

Our Managing Partner, Mr. Vincent Pang, was pleased to be invited to be part of the judging panel of The 26th Innovative Entrepreneur Awards Program organized by JCI City. The awards showcase outstanding ideas and the execution of entrepreneurs in developing innovative businesses.   Given the backdrop of an evolving pandemic in Hong Kong, it requires a grand vision as well as resilience to weather unprecedented challenges and uncertainties in the past years.  Vincent was particularly impressed with the quality of the award-winning businesses this year. He is looking forward to seeing the continuity of enthusiasm and perseverance in Hong Kong’s start-up ecosystem as well as creating more inspirational entrepreneur stories in the future.
 
<img src="../../../../../uploads/K62_8339_b670d63f56.JPG" alt="" width="600" />
<img src="../../../../../uploads/36cb455cc7f8ffb876ca08b6174b633_34951fa56c.jpg" alt="" width="600" />

banner1

As Judge of The 26th Innovative Entrepreneur Awards Program organized by Junior Chamber International City (JCI City)

Shanghai MicuRx Pharmaceutical Co., Ltd. has been successfully listed on the Shanghai Stock Exchange Science and Technology Innovation Board (STAR) on 5 August 2022. AVISTA Group is honored to be engaged in providing valuation services with regard to this listing application. Established in 2007, MicuRx is an innovative biopharmaceutical company focusing on therapeutics for infectious diseases with global independent intellectual property and competitiveness. MicuRx is committed to the discovery, development, and commercialization of innovative drugs for unmet medical needs. MicuRx has adhered to the principle of “Better therapy through superior medicine", focusing on the increasingly serious problem of global antimicrobial resistance. With the core competitiveness of solving clinical problems and differentiated innovation, MicuRx’s  goal is to provide more effective and safer therapeutic options for patients suffering from the most common and serious drug-resistant bacterial infections. Contezolid, one of MicuRx’s core products, is the first oxazolidinone antibiotic designed, developed, and marketed in China. According to the Frost &amp; Sullivan Report, the oxazolidinone antibiotic drugs continued its rising trend with market size of RMB 1.5 billion and a compound annual growth rate of 21.2% from 2016 to 2020. As the antimicrobial market is clearly structured and managed, safer and more reliable oxazolidinone antibiotic drugs will be marketed in China while the market size will expand to RMB 6 billion by 2030. Congratulations to Shanghai MicuRx Pharmaceutical Co., Ltd. (Stock Quote: 688373.SH) on its successful listing on the Science and Technology Innovation Board of Shanghai on 5 August 2022. The issue price of the shares is RMB 8.16 per share, and the amount of funds raised is RMB 1.06 billion. 
 
<img src="../../../../../uploads/PPT_3697c69d03.png" alt="" width="600" height="450" />

Congratulations to Shanghai MicuRx Pharmaceutical Co., Ltd. (688373.SH) on its Successful Listing

We are very excited and pleased to be invited by the Royal Institution of Chartered Surveyors (RICS) to be the sponsor of its Hong Kong Annual Conference 2022 - From bricks and mortar to the metaverse.
The industry-leading conference will cover some trending topics such as how ESG initiatives affect asset values, what are the corporate strategy, and actions to achieve carbon neutral goals as well as the future of virtual assets in the metaverse and beyond.
Keeping abreast of the latest market trends is imperative to our professional advisory services. Enabling effective and well-informed decision-making, AVISTA proudly supports the RICS Hong Kong Annual Conference 2022.
<img src="../../../../../uploads/Hong_Kong_Annual_Conference_Supporting_Sponsor_Avist_5269cf3d96.png" alt="" width="600" /> 28th July 12:30 – 5pm &amp; 29th July 8:30 – 12:30 HK
Reserve your space today via<a href="https://www.rics.org/en-hk/events/conferences-seminars/hong-kong-annual-conference/"> https://www.rics.org/en-hk/events/conferences-seminars/hong-kong-annual-conference/</a>

图片1.jpg

As the Sponsor of the RICS Hong Kong Annual Conference 2022

Our Managing Partner, Mr. Vincent Pang, was pleased to be invited on 5 July to share his industry knowledge and experience with fellow participants of the CUHK Mentorship Programme (CUMP) 2022.
 
In the sharing session themed “Pathway to Be an ESG Professional”, Vincent tapped into his extensive management and industry expertise to provide insights into the current ESG megatrend and ecosystem in the capital market. Having seen a growing interest among the younger generations in this rising sector, Vincent offered tips on navigating a career in sustainability and how to unlock great success within the ESG space.
 
<img src="../../../../../uploads/happy_hours_with_CUMP_mentors_Series_Pathways_to_be_an_ESG_Professional_7e21fe20d5.png" alt="" width="600" height="849" />

money-2724241_1920

As Guest Speaker in Happy Hours with CUMP Mentors Series  

Our Managing Partner, Mr. Vincent Pang, was pleased to be invited by the Royal Institution of Chartered Surveyors (RICS) to deliver a topical webinar titled “How Does ESG Deliver ‘Sustainable’ Returns on Your Property Portfolio – from the Hong Kong Perspective” on 5 July 2022. The webinar received very positive response with over 400 registrants, mainly from commercial real estate and valuation sectors working with valuation firms, developers and consultancy firms. Given the escalating awareness over responsible investment, the ESG performance of property portfolio has been of concern for many property owners, facilities management, occupiers and investment funds. The webinar, hence, zoomed in on how the major stakeholders can adopt a more robust approach to sustainability in every stage of the property lifecycle. Complemented by a case study of multiple commercial developments in Hong Kong plus references from locally and globally recognized real estate ESG benchmarks, Vincent explored the pivotal role of ESG in managing climate risks, preserving and thus driving the property asset value and sustainable returns on the property portfolio. <img src="../../../../../uploads/1_c4fceddcbb.png" alt="" width="600" height="600" />
<img src="../../../../../uploads/2_b6bf09011c.png" alt="" width="600" height="334" />

As Speaker of RICS Webinar – “How Does ESG Deliver ‘Sustainable’ Returns on Your Property Portfolio – from the Hong Kong Perspective”

ClouDr Group Ltd. has been successfully listed on the Mainboard of HKSE on 6 July 2022. AVISTA Group is honored to be engaged in providing valuation services with regards to this listing application. Established in 2014, the digital healthcare unicorn provides medical supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. Aspired to become a leader in China’s digital solutions for chronic care, ClouDr‘s solutions cater to the needs of all major participants along the value chain and cover the entire cycle of digital chronic condition management inside and outside hospital, in which include in-hospital, pharmacy and individual chronic condition management solutions. According to the Frost &amp; Sullivan Report, ClouDr was the largest digital chronic condition management solution provider in China as well as the largest online medical services provider in 2021, in terms of numbers of SaaS installations in hospitals and pharmacies in China, and number of online prescriptions issued. <img src="../../../../../uploads/EN_ad_d8b49379d3.jpg" alt="" width="500" height="375" />

News